Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development.

Ahmad IftikharHamza HassanNimra IftikharAdeela MushtaqAtif SohailNathaniel RoskoRajshekhar ChakrabortyFaryal RazzaqSonia SandeepJason Neil ValentAbraham Sebastian KanateFaiz Anwar

Published in: Antibodies (Basel, Switzerland) (2019)

Combination therapy using mAbs such as indatuximab, pembrolizumab, lorvotuzumab, siltuximab or dacetuzumab with chemotherapy agents produced better outcomes as compared to monotherapies. Further clinical trials investigating mAbs targeting CD38 used in combination therapy are warranted.

Keyphrases

combination therapy
clinical trial
multiple myeloma
phase ii
cancer therapy
locally advanced
randomized controlled trial
squamous cell carcinoma
metabolic syndrome
open label
adipose tissue
rectal cancer
skeletal muscle
nk cells
double blind
phase iii
chemotherapy induced